7
Views
10
CrossRef citations to date
0
Altmetric
Original Article

U.V. Enhanced Reactivation of U.V.- and γ-irradiated Adenovirus in Cockayne Syndrome and Xeroderma Pigmentosum Fibroblasts

&
Pages 625-647 | Received 21 Jan 1982, Accepted 17 Nov 1982, Published online: 03 Jul 2009
 

Summary

U.V.-enhanced reactivation (UVER) of both U.V.-irradiated and γ-irradiated human adenovirus type 2 (Ad 2) was examined following the infection of a variety of Cockayne Syndrome (CS) and Xeroderma pigmentosum (XP) fibroblast strains which had been pre-irradiated with U.V. light. U.V.-irradiated or non-irradiated fibroblasts were infected with either non-irradiated or irradiated Ad 2, and at 48 hours after infection cells were examined for the presence of viral structural antigens (Vag) using immunofluorescent staining. Normal levels of UVER (i.e. 2–4 fold) of U.V.- and of γ-irradiated Ad 2 were detected in 2 CS strains (CS IBE and CS 3BE), 2 XP complementation group A strains (XP 12BE and XP 25RO) and 2 XP complementation group D strains (XP 5BE and XP 6BE), although the U.V. doses to these mutant cells which resulted in peak UVER values (0·2 J m−2 for XP 25RO, 0·14 J m−2 for XP 12BE, 0·8 J m−2 for XP 5BE and XP 6BE, and 1·6–5·0 J m−2 for CS 1BE and CS 3BE) were considerably lower than those yielding peak UVER in normal strains (10–15 J m−2). XP variant strains (XP 4BE and XP 115LO), however, showed substantially lower levels of UVER than normal strains.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.